Edwards Non Current Liabilities Total from 2010 to 2024

EW Stock  USD 71.27  0.79  1.12%   
Edwards Lifesciences Non Current Liabilities Total yearly trend continues to be fairly stable with very little volatility. Non Current Liabilities Total will likely drop to about 800.7 M in 2024. During the period from 2010 to 2024, Edwards Lifesciences Non Current Liabilities Total regression line of quarterly data had mean square error of 124360.5 T and geometric mean of  851,530,524. View All Fundamentals
 
Non Current Liabilities Total  
First Reported
1999-12-31
Previous Quarter
1.4 B
Current Value
1.4 B
Quarterly Volatility
557.6 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Edwards Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edwards Lifesciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 89.7 M, Interest Expense of 10.6 M or Selling General Administrative of 1.8 B, as well as many indicators such as Price To Sales Ratio of 4.36, Dividend Yield of 0.0 or PTB Ratio of 4.82. Edwards financial statements analysis is a perfect complement when working with Edwards Lifesciences Valuation or Volatility modules.
  
Check out the analysis of Edwards Lifesciences Correlation against competitors.

Latest Edwards Lifesciences' Non Current Liabilities Total Growth Pattern

Below is the plot of the Non Current Liabilities Total of Edwards Lifesciences Corp over the last few years. It is Edwards Lifesciences' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edwards Lifesciences' overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Total10 Years Trend
Slightly volatile
   Non Current Liabilities Total   
       Timeline  

Edwards Non Current Liabilities Total Regression Statistics

Arithmetic Mean1,071,893,840
Geometric Mean851,530,524
Coefficient Of Variation47.71
Mean Deviation420,407,392
Median1,302,400,000
Standard Deviation511,395,849
Sample Variance261525.7T
Range1.7B
R-Value0.75
Mean Square Error124360.5T
R-Squared0.56
Significance0
Slope85,454,119
Total Sum of Squares3661360T

Edwards Non Current Liabilities Total History

2024800.7 M
20231.4 B
20221.5 B
20211.6 B
20201.8 B
20191.4 B
20181.3 B

About Edwards Lifesciences Financial Statements

Edwards Lifesciences investors use historical fundamental indicators, such as Edwards Lifesciences' Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Edwards Lifesciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Current Liabilities Total1.4 B800.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Edwards Stock Analysis

When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.